Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 19192,129 employeesWebsite
A leading pharmaceutical company with strengths in infectious diseases, known for its achievements in HIV and COVID-19 treatments as a global research-driven firm.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Business Segment | 100% | ¥499.7B | ¥166.7B | 33.4% |
Close (Oct 30, 2026)
¥3,012+21.1% (1Y)
Shionogi +21.1% over 1Y, 8.9pt above the industry average (23 companies, +12.2%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥499.7B | ¥166.7B | ¥205.2B | ¥2.6T | +14.0% |
| 2025FY | ¥438.3B | ¥156.6B | ¥170.4B | ¥1.5T | +0.7% |
| 2024FY | ¥435.1B | ¥153.3B | ¥162.0B | ¥1.4T | +2.0% |
| 2023FY | ¥426.7B | ¥149.0B | ¥185.0B | ¥1.3T | +27.3% |
| 2022FY | ¥335.1B | ¥110.3B | ¥114.2B | ¥1.2T | +12.8% |
| 2021FY | ¥297.2B | ¥117.4B | ¥111.9B | ¥999.0B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
